Avicenna Biosciences website screenshot

Avicenna Biosciences

Avicenna Biosciences, Inc. is a Durham, North Carolina drug development company using machine learning-enhanced medicinal chemistry to accelerate the lead-to-candidate optimization process for small molecule drug development. Founded in 2020 and led by president and CEO Chris Meldrum, the company applies computational screening of candidate molecules for drug-like properties to the "last mile" of small molecule discovery, targeting neurodegenerative disease programs including Rho kinase inhibitors for Parkinson's disease and ALS. Avicenna raised a seed round led by DCVC Bio and has signed research collaborations with partners such as Molecure S.A. The company publishes no public developer portal, API, or machine-readable interface as of this enrichment pass; it is catalogued here as an AI-for-drug-discovery company profile rather than an API provider.

Avicenna Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biosciences, Life Sciences, Biotechnology, and Venture Backed.

Avicenna Biosciences’ developer surface includes product news and 6 more developer resources.

4.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-09-08 · rubric v0.20.0
0 APIs
CompanyBiosciencesLife SciencesBiotechnologyVenture BackedDCVC PortfolioDrug DiscoveryMachine-LearningMedicinal ChemistrySmall MoleculeNeurodegenerative DiseaseArtificial Intelligence

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-09-08 · rubric v0.20.0
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero: never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and several others — scorable at all.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/avicenna-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Submit an artifact on GitHub — free → Manage your own listing — the Influence plan, $499/mo →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Avicenna Biosciences Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

Access & Security 1

Authentication, authorization, and security posture

Company 4

The organization behind the API

Other 1

Properties that don't map to a standard resource type

Source (apis.yml)

apis.yml Raw ↑
aid: avicenna-biosciences
name: Avicenna Biosciences
description: Avicenna Biosciences, Inc. is a Durham, North Carolina drug development company using machine learning-enhanced
  medicinal chemistry to accelerate the lead-to-candidate optimization process for small molecule drug development. Founded
  in 2020 and led by president and CEO Chris Meldrum, the company applies computational screening of candidate molecules for
  drug-like properties to the "last mile" of small molecule discovery, targeting neurodegenerative disease programs including
  Rho kinase inhibitors for Parkinson's disease and ALS. Avicenna raised a seed round led by DCVC Bio and has signed research
  collaborations with partners such as Molecure S.A. The company publishes no public developer portal, API, or machine-readable
  interface as of this enrichment pass; it is catalogued here as an AI-for-drug-discovery company profile rather than an API
  provider.
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://images.ctfassets.net/5je0qvum28n8/5gAbv4QZiCZIcbSssrG929/bf3447db4edfba83dea17dbd7abcb123/default-share-image.jpg?w=1200&h=630&q=65
url: https://raw.githubusercontent.com/api-evangelist/avicenna-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biosciences
- Life Sciences
- Biotechnology
- Venture Backed
- DCVC Portfolio
- Drug Discovery
- Machine-Learning
- Medicinal Chemistry
- Small Molecule
- Neurodegenerative Disease
- Artificial Intelligence
tags_raw:
- Company
- Biosciences
- Life Sciences
- Biotechnology
- Venture Backed
- DCVC Portfolio
- Drug Discovery
- Machine Learning
- Medicinal Chemistry
- Small Molecule
- Neurodegenerative Disease
- Artificial Intelligence
apis: []
common:
- type: Website
  url: https://www.avicenna-bio.com/
- type: About
  url: https://www.avicenna-bio.com/approach
- type: Team
  url: https://www.avicenna-bio.com/team
- type: News
  url: https://www.avicenna-bio.com/news
- type: LinkedIn
  url: https://www.linkedin.com/company/avicenna-biosciences
- type: DomainSecurity
  url: security/avicenna-biosciences-domain-security.yml
- type: LLMsTxt
  url: llms/avicenna-biosciences-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 3
  pass: local-v1

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this
  • find_providersBrowse and filter every provider in the catalog.
  • get_provider_artifactsEvery artifact this provider publishes, grouped by type.
  • get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
  • get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
  • get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
  • get_provider_ratingPRO — composite, band, trend and facet scores.
  • apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
  • resolveTurn a domain, URL or GitHub org into the provider it belongs to.
  • find_cohortsEvery scored population of providers in the catalog.
All 92 tools →

Call it yourself

curl for this page
This provider
curl "https://apis.io/api/v1/providers/avicenna-biosciences"
All providers
curl "https://apis.io/api/v1/providers?limit=25"
Every operation they expose
curl "https://apis.io/api/v1/providers/avicenna-biosciences/operations?limit=25"
How their score was established
curl "https://apis.io/api/v1/providers/avicenna-biosciences/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no form to fill in. Signing in shares your email address with us — we store it to create your key and to recognise you if you sign in with another provider. See our Privacy Policy and Terms.

A second provider on the same verified email joins the account you already have.